Autoimmune Diseases  >>  BMS-986142  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BMS-986142 / BMS
NCT02843659 / 2016-000101-37: Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Terminated
2
45
US, Europe, RoW
BMS-931699, lulizumab, BMS-986142, Placebo
Bristol-Myers Squibb
Sjögren's Syndrome
07/17
07/17

Download Options